Overview of Prostavasin

Quick Facts

Feature	Detail
Active Ingredient	Alprostadil
Drug Class	Prostaglandin E1 (PGE1) Analog
Key Mechanism	Vasodilation, Platelet Aggregation Inhibition

Prostavasin is the trade name for a medication whose active ingredient is alprostadil. Alprostadil is a synthetic version of the naturally occurring substance Prostaglandin E1 (PGE1), a lipid compound with potent, hormone-like effects on the body. It belongs to the broader class of drugs known as prostaglandins.

Mechanism of Action and Therapeutic Use

Alprostadil works primarily through vasodilation, the widening of blood vessels, by relaxing the smooth muscles in the vessel walls. This action increases blood flow to the targeted areas. Additionally, it possesses the pharmacologic effect of inhibiting platelet aggregation, which helps prevent blood clot formation.

In clinical settings, Prostavasin (alprostadil) is used to improve blood flow in patients suffering from certain severe forms of Peripheral Arterial Disease (PAD), particularly critical limb ischemia (stage III and IV), where surgical intervention may not be possible or effective. Its vasodilatory properties help relieve pain and improve circulation in the affected extremities.

Regulatory References

What side effects are possible with Prostavasin?

Official Safety Profile of Alprostadil (Prostavasin)

The official safety information for alprostadil is organized by regulatory agencies to describe documented adverse reactions and safety characteristics.

Frequency-Classified Adverse Reactions

Adverse events are categorized based on their officially reported frequency in regulatory labels:

Very Common (Affecting 1 in 10 or more): Reactions observed at the administration site, such as localized pain or inflammation, and transient systemic effects like fever and flushing.
Common (Affecting 1 in 100 to less than 1 in 10): Musculoskeletal discomfort, including muscle spasms, and certain cardiovascular effects like bradycardia or hypotension.

Serious Adverse Reactions

Regulatory documents highlight reactions that carry a significant risk. These serious events include:

Priapism: A prolonged erection lasting over six hours, primarily associated with injection forms, which requires immediate attention.
Cardiovascular and Cerebrovascular Events: Documented serious risks include myocardial ischaemia, cardiac arrest, and cerebrovascular accidents (stroke).
Apnea: A cessation of breathing, which is a key safety concern requiring immediate ventilatory support when the drug is administered to neonates.

Population-Specific Safety Considerations

The official labels specify unique safety constraints for certain patient groups:

Neonates: Due to the risk of apnea, alprostadil is only to be used where ventilatory assistance is immediately available. Long-term use in this population is also associated with the potential for changes in long bones and gastrointestinal issues.
Preexisting Conditions: Use is constrained in patients with conditions that predispose them to priapism (e.g., sickle cell disease or multiple myeloma).

Safety Restrictions and Monitoring

Official safety documents define specific monitoring requirements. For certain routes of administration, regular physical examination is required to monitor for the development of penile fibrosis, and treatment must be discontinued if this or other structural changes are observed.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Prostavasin (alprostadil) overdose defines specific systemic and localized manifestations that require mandated emergency actions.

Feature	Official Regulatory Guidance
Documented Manifestations	Systemic overdosage may present with hypotension, pyrexia (fever), bradycardia, apnea, and flushing. Localized overdose is indicated by a prolonged erection or priapism.
Population Notes	Neonates weighing less than 2 kg are noted to have an increased risk for apnea following intravenous administration.
Emergency Actions Required	Discontinue the infusion immediately if apnea or bradycardia occurs. If pyrexia or hypotension occurs, the infusion rate should be reduced.

When to Seek Urgent Medical Help

Classification	Official Regulatory Constraint
Required Action	Immediate medical assistance must be sought for any erection that persists for longer than 4 hours.
Management Note	No specific antidote is documented in the official labeling; management is limited to supportive and symptomatic treatment.

Official Overdose Statements

The most severe local sign of overdose is priapism, an erection lasting over six hours.
The patient must be under medical supervision until systemic effects have resolved or until detumescence has occurred.

The regulatory documents establish a clear dichotomy in the overdose profile: time-critical localized emergencies and systemic instability. Immediate help-seeking is mandated for prolonged localized effects, reflecting the time-sensitivity of that condition. For systemic effects, the official guidance emphasizes that management is restricted to symptomatic and supportive treatment due to the lack of a specific antidote, requiring procedural steps like cessation or reduction of the drug infusion.

Therapeutic Uses of Prostavasin

What Prostavasin Treats: Main Uses and Benefits

Prostavasin is used to provide supportive therapeutic benefits in situations where symptoms of severely restricted blood flow in the peripheral arteries are present. It is generally applied in settings marked by temporary physiological imbalance where these symptoms are intense and create noticeable physiological strain. Alprostadil is relevant for conditions characterized by periods of heightened symptoms associated with peripheral arterial occlusive diseases.

Easing Severe Physical Discomfort

The medication plays a role in managing symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort and symptoms that create noticeable physiological strain. This supportive effect helps to improve day-to-day comfort during symptomatic periods, and contributes to easing the overall symptom load associated with poor circulation. The application is relevant across domains where additional symptomatic support is needed, aligning with the management of challenging symptomatic phases.

Supporting Limb Tissue and Healing

Prostavasin is applied across domains where additional symptomatic support is needed for managing symptoms related to a lack of blood supply and tissue lesions. It is commonly used when short-term symptomatic assistance is needed during phases of increased distress or discomfort. It assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

Quick Fact: Relief for Pain and Strain

Prostavasin is considered relevant for easing symptoms that interfere with daily functioning, specifically symptoms related to physical discomfort and functional stress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Prostavasin?

The population eligibility for Prostavasin (alprostadil intravenous formulation) is strictly defined by regulatory documents, focusing on specific clinical conditions and patient characteristics.

Eligibility Scope

Classification	Population Details (Regulatory Statement)
Allowed Use	Adults with severe peripheral arterial occlusive disease (Critical Limb Ischemia); or neonates with ductal-dependent congenital heart defects.
Contraindicated	Patients with known hypersensitivity to alprostadil or any of its excipients. Also, neonates with Respiratory Distress Syndrome (hyaline membrane disease).
Conditional Use	Patients with a history of unstable cardiovascular disorders or transient ischaemic attacks (TIA) require caution.

Population-Specific Limitations

The medicine is generally not indicated for use in female patients for the treatment of peripheral arterial disease. For age-related use, the injection is not indicated for children or adolescents for the PAD treatment. Use in adults with renal or hepatic impairment requires caution, as slower clearance from the body may increase the drug's effects. Additionally, due to its effect on platelets, caution is necessary when the patient is concurrently taking anticoagulant medications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction profile of Alprostadil (the active ingredient in Prostavasin), based on governmental regulatory information.

Pharmacodynamic Interactions

The primary documented interactions involve additive effects related to the drug's vasodilatory and anti-platelet properties:

Other Vasoactive Agents: Co-administration with other treatments for erectile dysfunction (e.g., sildenafil) or other vasoactive agents injected intracavernosally is generally not recommended. This restriction is due to the unstudied potential for additive hypotensive effects or the risk of inducing a prolonged erection.
Anticoagulants and Platelet Inhibitors: Medicines such as warfarin, heparin, or other platelet aggregation inhibitors may increase the risk of localized bleeding at the injection site when co-administered with Alprostadil.
Antihypertensives: Alprostadil may enhance the effects of other antihypertensive or vasodilative agents, leading to a potential for increased blood pressure lowering.

Pharmacokinetic and Population Considerations

Pharmacokinetic Interactions: Official regulatory documents often state that formal pharmacokinetic drug-drug interaction studies have not been conducted, as the drug is rapidly metabolized locally.

Population Note: Patients with hepatic impairment may experience altered disposition kinetics, including a documented increase in systemic exposure ( C max) of the parent drug compared to healthy individuals, which may heighten the relevance of pharmacodynamic interactions.

Mechanism of Action

Targeting EP Receptors for Vasodilation

The drug’s core action is the direct agonism of specific Prostaglandin E receptors ( EP2/ EP4) found on blood vessel walls. This binding triggers a swift internal molecular cascade that dramatically elevates cellular cyclic AMP ( cAMP), the key second messenger that forces vascular smooth muscle cells to relax. This relaxation leads to vasodilation, a widening of arteries and arterioles, resulting in a reduction of peripheral resistance and an increase in local blood perfusion.

cAMP Activity and Platelet Stabilization

The same mechanism of cAMP increase extends to circulating platelets, where the heightened cAMP levels actively inhibit the biochemical signals required for them to stick together. This anti-aggregatory effect reduces the probability of platelet cohesion and subsequent thrombus formation within the vasculature. This complementary action combines with the primary vasodilatory effect to modulate the overall rheological and flow properties of the blood within peripheral circulation.

️ Mechanism Limitation: Rapid Metabolic Inactivation

The mechanism is functionally constrained by the drug’s rapid metabolic inactivation. Up to 80% of the active compound is quickly metabolized through pulmonary beta- and omega-oxidation after passing through the lungs. This inactivation results in a short duration of action for the active compound.

Dosage and Administration Information

How to Use Prostavasin

The administration of Prostavasin (alprostadil) is governed by specific protocols for the treatment of severe Peripheral Arterial Disease (PAD). Its usage is strictly confined to specialized clinical settings, reflecting the need for careful administration and monitoring.

Official Administration Guidelines

Element	Official Labeled Instruction
Route of Administration	Exclusively via continuous infusion into a large vein (intravenous, IV) or an artery (intra-arterial, IA).
Dosage Regimens	IV: Typically 2 x 40 micrograms per day (twice daily) or 1 x 60 micrograms per day (once daily). IA: Usually 1 x 10-20 micrograms per day.
Frequency and Timing	The 40 microgram IV dose is generally infused over two hours. The regimen follows a daily pattern over a defined, short-term treatment course.
Preparation	The concentrate for solution must be diluted freshly with a compatible solution before administration. In-use stability dictates that the prepared solution must be used promptly.

Procedural and Population Constraints

The required use of a parenteral route structures administration as a hospital-supervised procedure. Treatment is organized as a short-term course of several weeks, reflecting its role in acute support. Guidelines also address high-level population adjustments; for instance, a reduced starting dose, such as 2 x 20 micrograms IV, is indicated for patients with pre-existing renal impairment. These instructions collectively define the precise methodology, dosage constraints, and environmental context under which the medicine must be used.

Recent Clinical Evidence

Recent Clinical Evidence Summary

Prostavasin (Alprostadil) is a synthetic analogue of prostaglandin E1 (PGE1) that is studied for its vasodilatory and platelet aggregation-inhibiting properties. The main area of research for the intravenous formulation is in conditions involving severely restricted blood flow.

Focus on Peripheral Arterial Occlusive Disease (PAOD)

Clinical trials have primarily focused on participants with advanced stages of Peripheral Arterial Occlusive Disease (PAOD), specifically Fontaine stages III and IV (critical limb ischemia). These studies evaluate the effect of the drug on symptom relief and the progression of tissue damage.

Objective: To determine if the administration of Alprostadil affects clinical outcomes, particularly in patients with severe symptoms who have limited alternative treatment options.

Key Findings from Clinical Trials

Research examined several metrics to assess the clinical effect:

Walking Distance: In a study of patients with intermittent claudication (PAOD stage IIb), intravenous administration was associated with an increase in pain-free walking capacity compared to placebo.
Healing and Amputation Rates: Studies in patients with critical limb ischemia (stages III and IV) evaluated the drug's effect on the rate of wound healing and the need for amputation over a follow-up period.
Safety Profile: Clinical data reports that the most common adverse events related to intravenous use include flushing, headache, and dizziness, which are generally transient. Researchers continuously monitor for systemic effects, including hypotension and tachycardia.

Further research continues to explore the use of Alprostadil in other conditions characterized by vascular compromise, such as Systemic Sclerosis and Raynaud phenomena, and to refine its potential role in complex vascular management.

Frequently Asked Questions (FAQ)

Common questions about Prostavasin (FAQ)

Q: Is Prostavasin used for long-term treatment or is it usually temporary?

According to official administration guidelines, Prostavasin treatment is typically prescribed as a short-term course lasting several weeks. This is consistent with the drug's approved role in managing severe peripheral arterial disease. Regulatory documents define the precise duration of the treatment course for this specific use.

Q: What kind of research has been done on the long-term use of Prostavasin?

Clinical research has primarily focused on evaluating the drug's efficacy and safety during the short-term treatment course for critical limb ischemia. However, official safety labels for its use in neonates (for an unlisted indication) mention that extended use in that population is associated with the potential for changes in long bones and gastrointestinal issues.

Q: How quickly do patients usually start noticing changes after using Prostavasin?

The mechanism of action for Prostavasin involves a process intended to produce a rapid effect, as it causes a direct molecular cascade that leads to immediate smooth muscle relaxation and vasodilation. While the active drug is metabolically inactivated quickly, leading to a short duration of action, the exact time frame for a patient to notice significant clinical changes is not consistently specified in general patient information.

Q: What should I know about Prostavasin if I am planning to get pregnant?

Official documents state that the medicine is not indicated for use in female patients for the treatment of peripheral arterial disease. Furthermore, due to animal studies suggesting the drug may cause fetal harm, official product information for male patients may include a recommendation to use a barrier method (such as a condom) during intercourse to prevent exposure via seminal fluid.

Q: Are there any specific safety classifications for Prostavasin related to older adults?

While no unique problems specific to the elderly have been documented, official warnings do note that older patients are more likely to have age-related kidney problems. For this reason, caution is advised, and the need for a dose adjustment may be a consideration.

Q: Can Prostavasin be used for conditions not related to circulation in the legs?

Yes, official documentation indicates that while the intravenous formulation is used for severe peripheral arterial disease (PAD), the drug is also approved for use in neonates with certain ductal-dependent congenital heart defects. This second, non-PAD indication shows use beyond circulation issues in the limbs.

Q: Can Prostavasin be used if I have severe low blood pressure?

Official documents include warnings for use in patients with pre-existing hypotension (low blood pressure). Since Prostavasin is a potent vasodilator (it widens blood vessels) and can lower blood pressure, this pre-existing condition may require specific precautions during treatment.

Q: Does Prostavasin affect blood sugar levels?

Official regulatory documents list hyperglycemia (an increase in blood sugar) as a reported adverse reaction. This finding means that an effect on blood sugar is possible, although it is documented to occur in only a small percentage of patients in clinical trials.

Q: Are there reports of dizziness or faintness while taking Prostavasin?

Yes, official safety profiles derived from clinical data list side effects that include dizziness, light-headedness, and fainting (syncope). These effects are related to the drug's action as a vasodilator on the cardiovascular system.

Q: Do any official documents describe potential long-term risks associated with Prostavasin?

The official safety labels for the drug's use in neonates (for ductal-dependent congenital heart defects) specifically mention that extended use is associated with the potential for changes in long bones and gastrointestinal issues. For the PAD indication, treatment is defined as short-term.

Q: Does Prostavasin interact with common pain relievers like ibuprofen?

Regulatory information indicates that Prostavasin, which inhibits platelet activity, may have an additive effect with other platelet aggregation inhibitors, such as ibuprofen. Due to the potential for additive effects, the co-administration of these drug classes may be associated with an increased risk of localized bleeding at the administration site.

Q: Are there any foods or beverages that could interact with Prostavasin?

Patients are officially advised to discuss the use of alcohol with their doctor during the course of treatment. Official drug information indicates that consuming alcohol may potentially decrease the effectiveness of the medication.

Q: Is Prostavasin used in different ways for different stages of the condition?

Research evidence supporting the drug's use covers various stages of Peripheral Arterial Occlusive Disease (PAOD). While it is primarily studied and approved for advanced stages, such as critical limb ischemia (Fontaine stages III and IV), studies have also been conducted on its effect in patients with intermittent claudication (stage IIb).

Q: What does the research say about Prostavasin helping with wound healing?

Clinical trials in patients with critical limb ischemia have specifically evaluated the drug's effect on the rate of wound healing in the affected extremities. The research also tracks the drug's impact on clinical outcomes, including the need for amputation over the follow-up period.

Q: What precautions are taken regarding the injection site for Prostavasin?

Instructions for safe administration include local procedural precautions such as cleaning the injection site with an alcohol wipe before insertion. Care is also taken during the procedure to avoid visible superficial veins due to the possibility of localized bleeding or inflammation.

Q: What are the official guidelines regarding driving while undergoing treatment with Prostavasin?

Due to the drug's potential to cause side effects like dizziness or fainting (syncope), official guidelines recommend caution regarding activities that require alertness, such as driving or operating heavy machinery. This caution is generally advised until the patient understands how the medication affects them.

How should Prostavasin be stored and disposed of?

How to Store and Dispose of Prostavasin?

The official storage and disposal requirements for alprostadil products, including Prostavasin and related formulations, are defined by regulatory authorities to ensure stability and safety.

Storage Requirements

Unopened Product: Store the medication as directed by the specific product label, which often mandates storage in a refrigerator (2 C to 8 C) or at controlled room temperature (20 C to 25 C). Do not freeze the product.
Protection: Keep the container tightly closed and protected from light and moisture. Keep all medication out of the sight and reach of children.
Post-Reconstitution: The stability of the reconstituted or diluted solution is strictly limited. Solutions must typically be used immediately or within a short, specified period (such as 8 or 24 hours), after which they must be discarded. Do not refrigerate reconstituted solutions.

Handling and Disposal

Sharps: Needles and syringes are for single use only. Dispose of all used needles and syringes immediately in an FDA-cleared, puncture-resistant sharps disposal container according to local medical waste regulations.
General Waste: Any unused product or waste material should be disposed of in accordance with local requirements, such as through community drug take-back programs.

Prostavasin